Click here for more information about Algenuity
Click here for more information about LiqofluxPhenometrics Buy 3 Get 1 Free
Visit cricatalyst.com!Evodos Separation Technology Check out more of The Buzz spacer

Shanghai Green Valley launches brown algae-based Alzheimer’s drug

January 6, 2020
AlgaeIndustryMagazine.com

An extract of brown algae called Oligomannate was approved for clinical trials. Photo: Wright Patterson AFB Courtesy Graphic

Bloomberg News reports that a newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe this year as the country’s first novel therapy for the incurable disease seeks global legitimacy.

Shanghai Green Valley Pharmaceutical Co. (Green Valley) plans to recruit around 2,000 patients with mild-to-moderate Alzheimer’s for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company’s Vice President Li Jinhe said.

The drug, an extract of brown algae called Oligomannate, was granted conditional approval in China last month. It comes in a 150mg capsule and went on sale in the country on Dec. 29. Patients will need to take three capsules twice a day, according to the drug’s package insert. A week’s treatment costs 895 yuan (US$128).

Green Valley announced these plans in a press conference in Beijing nearly two months after making global headlines for saying it got approval from China’s regulator for the first new Alzheimer’s drug in 17 years.

The company said it plans to invest $3 billion in the next 10 years for investigations and global trials to understand its working mechanism and expand its use in treating diseases such as Parkinson’s and vascular dementia.

Green Valley plans to file an application for clinical trials with the U.S. Food and Drug Administration in February 2020. It also wants to secure the Fast Track designation, said Green Valley’s Li. This tag helps expedite regulatory review of drugs that treat serious conditions or fill an unmet medical need. The company is also exploring partnerships with global drug makers to speed up clinical trials and help launch the product outside China, Li said.

The Green Valley therapy works differently from the approach taken on Alzheimer’s by western drug developers. Its Oligomannate drug – the name refers to a type of sugar extracted from brown seaweed – is unusual in that it does not target beta amyloid, a protein that forms clumps of plaque in the brain, clogging it in patients with Alzheimer’s.

Oligomannate instead seeks to readjust microbiome in the gut, which ultimately leads to reduced neuron inflammation in the brain and slows the progression of the disease, according to the company.

In Chinese trials, the drug had statistically improved cognitive function in patients suffering from mild-to-moderate Alzheimer’s as early as week four, Green Valley said in a November statement. Its success, however, has been met with skepticism from Alzheimer’s researchers, who say that details are scant on its clinical trials in China.

“Doubts always accompany scientific discovery,” says Geng Meiyu, a researcher with Shanghai Institute of Materia Medica who led the discovery and research of the drug, adding that Green Valley will continue to look into the drug’s working mechanism among humans through further studies and scientific collaboration. “This is just the first step of a long march,” said Geng.

Read More

More Buzz…

Copyright ©2010-2020 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

twittertopbarlinks_eventstopbarlinks_requesttopbarlinks_archives

From The A.I.M. Archives

— Refresh Page for More Choices
Gerard de Souza reports for the Hindustan Times that researchers at the CSIR-National Institute of Oceanography Goa (India) have found a cleaner, cheaper method to grow b...
Judith Lewis Mernit writes in e360.yale.edu that an experiment being conducted by animal science professor Ermias Kebreab at the University of California, Davis, is testi...
Biotechnologists from Aarhus University have demonstrated how the rare properties of an atypical light-dependent enzyme can be used with a photo-bio-catalytic continuous ...
Maiki Sherman, traveling with New Zealand Prime Minister Jacinda Ardern, reports for 1News Now that new innovation partnerships have been signed between New Zealand and J...
Steve Fountain writes in fortstocktonpioneer.com that, amid the 800-page law that last month set the country’s farm policy through 2023, is the expansion of federal suppo...
Mazda U.K. has announced that they are currently involved in joint research projects and studies as part of an ongoing industry-academia-government collaboration to promo...
Skara Bohny reports in Stuff.co.nz that New Zealand’s Cawthron Institute is receiving funding as part of the High-Value Nutrition’s (HVN) National Science Challenge to de...
Milenio.com reports that BiomiTech, a Mexican company, won a prestigious innovation award for its air purification system at the Contamination Expo Series 2018 held in Bi...
Nestlé has entered into a partnership with Corbion to develop the next generation of microalgae-based ingredients, enabling the companies to deliver sustainable, tasty an...
The problem of access to safe drinking water in most parts of Bangladesh is a persistent challenge. Now, a team of scientists from Uppsala University, Sweden, and Dhaka U...
AlgaEnergy, a Spanish biotechnology company specializing in the production and commercial applications of microalgae, and Yokogawa Electric Corporation, a leading provide...
Susan Kraemer writes in solarpaces.org that to use solar thermal energy to convert farmed algae to fuel, the solar fuels research team at Australian National University (...